Merck: 'therapeutic breakthrough' for antibody-conjugate
(CercleFinance.com) - On Tuesday Merck announced that the FDA had granted breakthrough therapy status to its antibody-conjugate project for the treatment of a specific form of bronchial cancer.
The pharmaceutical group claims to have obtained this status from the US health agency for sacituzumab tirumotecan (sac-TMT) in the treatment of certain patients with advanced or metastatic non-squamous non-small cell lung cancer with EGFR gene mutations.
More specifically, the decision concerns patients expressing a deletion of exon 19 or exon 21 whose disease has progressed during or after chemotherapy accompanied by treatment with tyrosine kinase inhibitors
The investigational drug conjugate antibody Sac-TMT, developed in collaboration with Kelun-Biotech, is currently in ten Phase 3 clinical trials, either as a single agent or in combination with the immunotherapy Keytruda.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The pharmaceutical group claims to have obtained this status from the US health agency for sacituzumab tirumotecan (sac-TMT) in the treatment of certain patients with advanced or metastatic non-squamous non-small cell lung cancer with EGFR gene mutations.
More specifically, the decision concerns patients expressing a deletion of exon 19 or exon 21 whose disease has progressed during or after chemotherapy accompanied by treatment with tyrosine kinase inhibitors
The investigational drug conjugate antibody Sac-TMT, developed in collaboration with Kelun-Biotech, is currently in ten Phase 3 clinical trials, either as a single agent or in combination with the immunotherapy Keytruda.
Copyright (c) 2024 CercleFinance.com. All rights reserved.